This thinking may change thanks to the new finding by scientists in the Laboratory of
Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.
As for therapeutics, Xavier, who is also the Kurt Isselbacher Chair in Medicine
at Harvard Medical School and Co-Director of the Center for Microbiome Informatics and Therapeutics
at MIT, says that knowing which species are absent and which are flourishing in the gastrointestinal tract of children with T1D may help make it possible to slow progression of the disease after onset by revealing ways to manipulate the microbiome and, in turn, microbiome - induced
immunoregulation.